Clinical Research Directory

Inclusion Criteria: Parts A and B: * Body mass index of 18 kg/m2 at screening. * Agree to comply with all protocol requirements. * Able to provide written informed consent. * Agree to defined medications and monitoring as instructed by the site. Other protocol-defined inclusion criteria will apply. Part B Only: \- Must meet the criteria for moderate-to-severe TED. Exclusion Criteria: Part A and Part B: * Significant medical conditions or physical findings that may affect participant safety. * Active liver or kidney dysfunction at screening. * Known hypersensitivity to monoclonal antibody products and/or subcutaneous injections. * Blood pressure or ECG abnormalities at screening. * Pregnancy of plans for pregnancy; breastfeeding. * The participant has a history of alcohol or substance abuse within the last 12 months before screening. * Use of any investigational drug within 60 days prior to the first injection of study drug. * History of treatment with teprotumumab or other anti-IGF-1R monoclonal antibodies. Other protocol-defined exclusion criteria apply.